Risk of COVID-19-related surgery postponements and supply chain disruptions
First written in FY2020. 4 of 11 entries say "Restated". Latest entry: FY2024.
Japan Medical Dynamic Marketing moved to the "Worse" side of this theme in 2020, 6 years before the typical company in this theme (2026).
2 other companies' latest entry also says "Restated".
- FY2024RestatedAnnual report
「There is a risk that the Group's profit or loss and financial position could be affected if medical institutions postpone non-urgent procedures, such as artificial-joint replacement surgery, in accordance with health-administration guidelines in each country amid the spread of infectious diseases.」
The risk of postponed surgeries and an impact on profit or loss arising from the spread of infectious diseases continues to be disclosed as an infectious-disease risk. - FY2024-Q1MitigatedAnnual report
「In Japan's artificial-joint market, case volumes have been gradually increasing since COVID-19 was reclassified as a Category 5 disease. Sales of "Entrada" have remained strong, growing at a double-digit rate, and the number of cases acquired for total hip arthroplasty (THA and BHA) increased. As a result, sales in Japan were ¥1,170 million, up 3.2% year on year.」
Following the reclassification of COVID-19 as a Category 5 disease, case volumes in Japan's artificial-joint market have gradually increased, and sales rose 3.2% year on year. Although the disclosure does not state that the impact of COVID-19 has disappeared, it indicates that its impact on domestic case volumes is easing. - FY2023-Q3RestatedAnnual report
「Accounting estimates for the nine-month period of the fiscal year under review were calculated at reasonable amounts based on information available when the quarterly consolidated financial statements were prepared. However, there is uncertainty regarding the future spread of COVID-19 and when it will subside. If the status of COVID-19 infections, the economic environment, or other factors differ from current assumptions, the operating results and financial position of the Group may be affected. There have been no material changes from the assumptions as of the end of the previous consolidated fiscal year.」
The uncertainty over the spread and containment of COVID-19 and its potential impact on business performance and financial position continues to be disclosed, with no material changes from the assumptions as of the end of the previous consolidated fiscal year. - FY2023-Q2RestatedAnnual report
「Accounting estimates for the six-month period of the fiscal year under review were calculated at reasonable amounts based on information available when the quarterly consolidated financial statements were prepared. However, there is uncertainty regarding the future spread of COVID-19 and when it will subside. If the status of COVID-19 infections, the economic environment, or other factors differ from current assumptions, the operating results and financial position of the Group may be affected. There have been no material changes from the assumptions as of the end of the previous consolidated fiscal year.」
The uncertainty regarding the spread of COVID-19 and when it will subside, and the potential impact on operating results and financial position, was disclosed again. It was stated that there had been no material changes from the assumptions as of the end of the previous consolidated fiscal year. - FY2023-Q1RestatedAnnual report
「There is considerable uncertainty regarding the future spread of COVID-19 and when it will subside. If the status of COVID-19 infections, the economic environment, or other factors differ from current assumptions, the operating results and financial position of the Group may be affected. There have been no material changes from the assumptions as of the end of the previous consolidated fiscal year.」
The uncertainty regarding the spread of COVID-19 and when it will subside, and the potential impact on operating results and other matters, continued to be disclosed. It was stated that there had been no material changes from the assumptions as of the end of the previous fiscal year. - FY2022-Q2WorsenedAnnual report
「Meanwhile, sales to external customers in the United States recovered, rising 22.3% year on year in U.S. dollars and 26.3% after translation into yen to ¥3,392 million. However, from the second quarter onward, U.S. sales did not reach the level of the same quarter two years earlier, before the COVID-19 pandemic, because scheduled surgeries were postponed again as infections resurged in the United States.」
In the United States, scheduled surgeries were postponed again as infections spread, and the recovery in sales did not reach pre-pandemic levels. The disclosure described a renewed deterioration in risk, following the recovery trend in the previous quarter. - FY2022-Q1MitigatedAnnual report
「Although the cumulative first quarter of the current consolidated fiscal year continued to be affected by COVID-19, our group’s business environment began to recover. Net sales were ¥4,537 million, up ¥1,128 million, or 33.1%, year on year; operating profit was ¥554 million, up ¥312 million, or 129.0%; ordinary profit was ¥542 million, up ¥303 million, or 127.2%; and quarterly net income attributable to owners of the parent was ¥363 million, up ¥231 million, or 176.3%.」
Although the impact of COVID-19 continued, the business environment was recovering, and company-wide sales and profit exceeded the year-earlier levels. The disclosure did not state that the risk had disappeared. - FY2021-Q3WorsenedAnnual report
「However, as the number of people infected with COVID-19 rose sharply from November, medical institutions again decided to postpone or cancel surgeries, and the number of cases declined again. In addition, outpatients have been refraining from visiting medical institutions due to concerns about nosocomial infections, and the number of cases is not expected to recover simply in the fourth quarter.」
As infections increased again in the United States, surgeries were postponed or canceled again and the number of cases declined again. It was reported that a simple recovery was not expected in the fourth quarter. - FY2021-Q2MaterialisedAnnual report
「Sales declined as the number of procedures fell due to the impact of COVID-19 in Japan and the United States. Sales in Japan declined 3.5% year on year to ¥5,067 million, while sales to external customers in the United States fell 22.3% year on year in U.S. dollar terms and 24.0% after translation into yen to ¥2,685 million.」
The impact of fewer cases and postponed or canceled surgeries due to COVID-19 materialized as a 3.5% decline in domestic sales and a 22.3% decline in U.S.-dollar sales to external customers outside the United States. - FY2021-Q1MaterialisedAnnual report
「Sales declined as the number of procedures fell due to the impact of COVID-19 in Japan and the United States. Sales in Japan declined 8.0% year on year to ¥2,400 million, while sales to external customers in the United States fell 41.3% year on year in U.S. dollar terms and 42.5% after translation into yen to ¥1,008 million.」
The impact of fewer cases and postponed or canceled surgeries due to COVID-19 materialized as lower sales in Japan and the United States, with company-wide net sales down 21.9% year on year. - FY2020First statedAnnual report
「In the United States, as the number of COVID-19 patients rose sharply from March 2020, measures were taken to delay non-urgent surgeries in order to secure hospital beds for COVID-19 patients. Many joint replacement surgeries have already been postponed, and the number of surgeries has fallen sharply.」
Postponements and cancellations of joint replacement surgeries and other procedures had already occurred due to COVID-19, and the sharp decline in the number of surgeries was reported as a new business risk. The possibility of supply-chain disruptions was also indicated.